List of Excipients in API ensartinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ensartinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Xcovery Holdings Inc | ENSACOVE | ensartinib | 83076-1025 | AMMONIA | 2029-12-18 |
| Xcovery Holdings Inc | ENSACOVE | ensartinib | 83076-1025 | BUTYL ALCOHOL | 2029-12-18 |
| Xcovery Holdings Inc | ENSACOVE | ensartinib | 83076-1025 | CELLULOSE, MICROCRYSTALLINE | 2029-12-18 |
| Xcovery Holdings Inc | ENSACOVE | ensartinib | 83076-1025 | DEHYDRATED ALCOHOL | 2029-12-18 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ensartinib
Excipient focus: AMMONIA
ensartinib drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
ensartinib drug variants containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ensartinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: DEHYDRATED ALCOHOL
ensartinib drug variants containing DEHYDRATED ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing DEHYDRATED ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
ensartinib drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ensartinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ISOPROPYL ALCOHOL
ensartinib drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
ensartinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
ensartinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STEARIC ACID
ensartinib drug variants containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ensartinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Xcovery Holdings Inc | ensartinib | 83076-1025 |
| >Company | >Ingredient | >NDC |
ensartinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch